Factory 99% Resmetirom Powder CAS 920509-32-6 Chemical Intermediate Resmetirom

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A936
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Resmetirom
• CAS: 920509-32-6
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Resmetirom
Appearance	White Powder
CAS NO.	920509-32-6
Storage	Keep in a cool, dry, dark location

 

Resmetirom is an oral, liver-selective thyroid hormone receptor-β (THR-β) agonist. It is a novel therapeutic agent designed to target specific metabolic pathways in the liver, offering a potential treatment for metabolic dysfunction-associated fatty liver disease (MASH), formerly known as non-alcoholic steatohepatitis (NASH).

 

1. Treatment of MASH/NASH: Resmetirom is primarily applied for the treatment of patients with MASH, particularly those with liver fibrosis. By addressing the underlying metabolic disturbances, it aims to improve liver health and reduce the progression of liver disease.
2. Combination Therapy: It may be used in combination with other medications or therapeutic approaches, such as diet and exercise, to enhance the overall management of MASH/NASH.
3. Adjuvant Therapy: In some cases, Resmetirom may serve as an adjuvant therapy to support liver function and reduce inflammation while patients undergo other treatments for their condition.

1. Activation of THR-β in the Liver: Resmetirom selectively activates THR-β in the liver, which regulates various metabolic pathways involved in lipid metabolism. This activation leads to a reduction in liver fat accumulation and an improvement in liver function.
2. Reduction of Inflammation and Fibrosis: By modulating metabolic pathways, Resmetirom helps to reduce inflammation and fibrosis in the liver, which are key features of MASH/NASH.
3. Improvement in Sensitivity: Additionally, Resmetirom has been shown to improve sensitivity, which is beneficial for patients with MASH/NASH who often have associated resistance.